NCT07655440Not yet recruitingPhase 4
Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)
Comparative Outcomes of Migraine Preventives and Anti-CGRP Therapies for Tinnitus in Patients With Migraine: A Randomized Active-Comparator Controlled Trial (COMPACT-PM)
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
Many people with migraine also experience tinnitus - a persistent ringing, buzzing, or hissing in the ears - and research suggests these conditions share underlying biological mechanisms, including a protein called calcitonin gene-related peptide (CGRP) that is active in both the brain and the inner ear. COMPACT-PM is a randomized trial comparing two classes of migraine preventive medications in adults with bothersome tinnitus and a history of migraine: anti-CGRP therapies (newer injectable or oral agents that block CGRP or its receptor) versus conventional migraine preventives (antidepressants including amitriptyline, nortriptyline, and venlafaxine; antihypertensives including propranolol, verapamil, and candesartan; and the anticonvulsant topiramate). Participants are randomly assigned - like a coin flip - to one of the two treatment groups; neither group receives a placebo, as both receive active migraine treatment. The study's primary outcome is change in the Tinnitus Functional Index (TFI) over 24 weeks, with additional measures including hearing tests, balance assessments, auditory brainstem response testing, and a comprehensive symptom diary. The study is conducted at the Stanford Ear Institute and is funded by a philanthropic gift to the Department of Otolaryngology - Head \& Neck Surgery at Stanford University.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 29 May 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 31 Jul 2031
- Lead sponsor
- Stanford University
- Diseases
- Migraine
- NCT number
- NCT07655440
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 120
- From 1 Jul 2026 to the primary completion date, 31 Jul 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently receiving a CGRP-targeting medication (for participants being considered for the conventional arm) or a conventional migraine preventive medication listed in this protocol (for participants being considered for the CGRP arm) - to avoid within-arm ineligibility at randomization
- Known contraindication to all medications within the assigned study arm
- Known hypersensitivity or prior serious adverse reaction to a medication within the assigned study arm
Other illness
- History of serious cardiovascular event (myocardial infarction, stroke, or unstable angina) within 6 months of enrollment
- Severe hepatic or renal impairment that would contraindicate study medications
- Active psychiatric disorder requiring medication adjustment within 3 months of enrollment
- Active malignancy or life expectancy less than 12 months
Other
- Pulsatile tinnitus or objective tinnitus (tinnitus audible to examiner)
- Pregnancy, planned pregnancy during the study period, or breastfeeding
- Participation in any other interventional tinnitus treatment research protocol during the study period
- Inability to complete study procedures or follow-up visits in the judgment of the investigator
Who the study is looking for
- Age 18 years or older
- Non-pulsatile, subjective tinnitus present for at least 6 months
- Tinnitus Functional Index (TFI) score greater than 25 at screening, indicating at least mild-to-moderate tinnitus burden
- Current or past history of migraine, vestibular migraine, or episodic headache disorder, diagnosed by a physician or meeting ICHD-3 criteria
- Clinically appropriate candidate for migraine preventive therapy as determined by the treating clinician
- Stable medication regimen for at least 3 months prior to enrollment (no new medications started or stopped within 3 months of screening)
- Ability to provide written informed consent
- Ability to complete self-report questionnaires in English or with certified interpreter assistance
- Willingness to attend three in-person study visits over 24 weeks and complete daily symptom diaries
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.